ANI Pharmaceuticals Inc
NASDAQ:ANIP

Watchlist Manager
ANI Pharmaceuticals Inc Logo
ANI Pharmaceuticals Inc
NASDAQ:ANIP
Watchlist
Price: 57.86 USD -1.33% Market Closed
Market Cap: 1.2B USD
Have any thoughts about
ANI Pharmaceuticals Inc?
Write Note

Net Margin
ANI Pharmaceuticals Inc

1.1%
Current
-9%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
1.1%
=
Net Income
7.5m
/
Revenue
692.9m

Net Margin Across Competitors

Country US
Market Cap 1.2B USD
Net Margin
1%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 749.7B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 3.3T DKK
Net Margin
35%
Country US
Market Cap 372B USD
Net Margin
17%
Country US
Market Cap 257.3B USD
Net Margin
19%
Country CH
Market Cap 200.6B CHF
Net Margin
20%
Country UK
Market Cap 162.5B GBP
Net Margin
13%
Country CH
Market Cap 179.9B CHF
Net Margin
35%
Country US
Market Cap 146B USD
Net Margin
7%
No Stocks Found

ANI Pharmaceuticals Inc
Glance View

Market Cap
1.2B USD
Industry
Pharmaceuticals

ANI Pharmaceuticals, Inc. is a pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The company is headquartered in Baudette, Minnesota and currently employs 601 full-time employees. The company went IPO on 2000-05-04. The firm is focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The firm focuses on areas, including controlled substances, oncology products (anti-cancer), hormones and steroids, and complex formulations. The Company’s products include both branded and generic pharmaceuticals. Its generic products include Aspirin and Extended Release Dipyridamole, Bretylium Tosylate Injection USP, cholestyramine, Etodolac, Fluvoxamine, Indapamide, Nilutamide, Vancomycin and more. Its branded products include Arimidex (anastrozole) tablets, Atacand HCT Tablets, Atacand (candesartan cilexetil) Tablets, Casodex, Cortenema, Cortrophin gel, Cortrophin-Zinc, Inderal LA, Inderal XL, InnoPran XL, Lithobid, Reglan and Vancocin. The company operates across three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota and one is located in Oakville, Ontario.

ANIP Intrinsic Value
96.33 USD
Undervaluation 40%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
1.1%
=
Net Income
7.5m
/
Revenue
692.9m
What is the Net Margin of ANI Pharmaceuticals Inc?

Based on ANI Pharmaceuticals Inc's most recent financial statements, the company has Net Margin of 1.1%.